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Abstract 
Objectives. This study compared the performance of major heart failure (HF) risk models in predicting 
mortality and examined their utilization using data from a contemporary multinational registry. 
Background. Several prognostic risk scores have been developed for ambulatory HF patients, but their 
precision is still inadequate and their use limited. 
Methods. This registry enrolled patients with HF seen in participating European centers between May 2011 
and April 2013. The following scores designed to estimate 1- to 2-year all-cause mortality were calculated in 
each participant: CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality), GISSI-HF 
(Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure), MAGGIC (Meta-
analysis Global Group in Chronic Heart Failure), and SHFM (Seattle Heart Failure Model). Patients with 
hospitalized HF (n = 6,920) and ambulatory HF patients missing any variable needed to estimate each score 
(n = 3,267) were excluded, leaving a final sample of 6,161 patients. 
Results. At 1-year follow-up, 5,653 of 6,161 patients (91.8%) were alive. The observed-to-predicted survival 
ratios (CHARM: 1.10, GISSI-HF: 1.08, MAGGIC: 1.03, and SHFM: 0.98) suggested some overestimation of 
mortality by all scores except the SHFM. Overprediction occurred steadily across levels of risk using both the 
CHARM and the GISSI-HF, whereas the SHFM underpredicted mortality in all risk groups except the 
highest. The MAGGIC showed the best overall accuracy (area under the curve [AUC] = 0.743), similar to the 
GISSI-HF (AUC = 0.739; p = 0.419) but better than the CHARM (AUC = 0.729; p = 0.068) and particularly 
better than the SHFM (AUC = 0.714; p = 0.018). Less than 1% of patients received a prognostic estimate 
from their enrolling physician. 
Conclusions. Performance of prognostic risk scores is still limited and physicians are reluctant to use 
them in daily practice. The need for contemporary, more precise prognostic tools should be considered.  
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Predicting survival in heart failure (HF) has become increasingly important for optimal patient 
care (1). Accurate assessment of prognosis may allow clinicians to decide whether a patient with 
chronic HF would most likely benefit from certain diagnostic and therapeutic interventions, 
especially invasive tests and complex procedures such as ventricular assist device implantation and 
heart transplantation. With these goals, several prognostic risk models have been developed in the 
past years, with the Seattle Heart Failure Model (SHFM) being the most popular and most 
thoroughly validated (2). However, these scores are not routinely calculated in clinical practice (1–
4), primarily because of their poor reliability at the individual patient level (5) and also because 
treatments that specifically fit different levels of risk have not been established. A recent 
systematic review, which examined the characteristics of 20 prediction models for ambulatory HF 
patients, highlighted their inconsistent performance and called for new and more contemporary 
risk models (6). Thereafter, 2 new prognostic scores were proposed, the GISSI-HF (Gruppo 
Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico-Heart Failure) (7) and the 
MAGGIC (Metaanalysis Global Group in Chronic Heart Failure) (8). The latter, in particular, was 
developed from a dataset of more than 39,000 individual patients’ data from 30 studies (8) and 
recently validated using 2 large administrative datasets, but with a significant number of missing 
data, which were statistically imputed (5,9).  
 
Between 2011 and 2013, the European Society of Cardiology (ESC) promoted a multinational 
HF registry, which enrolled more than 9,000 ambulatory HF patients who were followed up for 1 
year or more. We tested and compared the performance of main prognostic risk scores in 
predicting 1- to 2-year survival in this contemporary population, and examined their use in daily 
clinical practice.  
METHODS  
STUDY POPULATION. 
The ESC Heart Failure Long Term Registry has been previously described (10–12). Between 
May 2011 and April 2013, HF patients presenting to participating European centers with age >18 
years were enrolled on a 1-day-per-week basis for 12 consecutive months, regardless of their left 
ventricular ejection fraction (LVEF). A diagnosis of HF was based on the clinical judgment of 
study investigators, which were primarily general cardiologists (10). The registry included 6,920 
hospitalized HF patients who were excluded from this analysis focused on chronic HF. The 
majority of ambulatory HF patients were enrolled in Southern Europe (58.4%), and the remaining 
in Eastern (18.0%), Western (7.5%), and Northern Europe (5.9%), North Africa (6.3%), and the 
Middle East (3.9%) (10). They were followed up in accordance with the usual practice of each 
center, but a mandatory follow-up visit at 12 months was requested. At enrollment visit, all study 
investigators were requested to answer the following question included in the case report form of 
each patient: “Was prognosis evaluated using a risk score?” Where a positive answer was given, 
the following risk scores were proposed: SHFM, CHARM (Candesartan in Heart Failure-
Assessment of Reduction in Mortality), GISSI-HF, MAGGIC, MECKI (Metabolic Exercise, 
Cardiac, Kidney Index), HF-ACTION (Heart Failure and A Controlled Trial Investigating 
Outcomes of Exercise TraiNing), and EMPHASIS (Eplerenone in Mild Patients Hospitalization 
and Survival Study in Heart Failure) (see below). Each local Institutional Review Board approved 
the registry, and all patients enrolled in the study signed an informed consent.  
SELECTION OF SCORES.  
The score selection process is described in Figure 1. The primary outcome of the ESC HF 
Long Term Registry was 1-year all-cause mortality. Due to between-country differences in the 
starting date of enrolment, there were varying follow-up times in the entire study group, with a 
median follow-up time of 373 days, and 9.7% of patients having more than 2 years of follow-up 
(10). Thus, we selected those risk scores designed to estimate all-cause mortality at a follow-up of 
approximately 1 to 2 years in ambulatory HF patients only. These included the GISSI-HF score 
(7), the MAGGIC score (8), the SHFM score (2) and the CHARM score (13). The latter was 
primarily designed to predict cardiovascular mortality plus HF hospitalization, but a secondary 
analysis was performed to estimate predictors of total mortality at approximately 2 years; the 
prognostic model derived from this secondary analysis was used in our work (13). MECKI (14) 
and HF-ACTION (15) scores were excluded because they are primarily based on cardiopulmonary 
exercise test parameters, which were not collected in the present registry. In addition, they were 
generally designed to predict outcomes different from all-cause mortality, as was the EMPHASIS 
score (16) (i.e., cardiovascular mortality plus HF hospitalization). Other risk scores obtained from 
smaller and older cohorts (i.e., <1,000 patients, before the year 2000) (6) or including HF patients 
discharged from hospital (17) were not considered in this analysis.  




The initial 7 risk scores listed across the top were proposed in the in the case report form of each patient at the enrollment 
visit. See text for details. CHARM ¼ Candesartan in Heart Failure-Assessment of Reduction in Mortality; CPET = 
cardiopulmonary exercise test; CV = cardiovascular; EMPHASIS = Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure; GISSI-HF = Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico-
Heart Failure; HF = heart failure; MAGGIC = Meta-analysis Global Group in Chronic Heart Failure; MECKI = Metabolic 
Exercise, Cardiac, Kidney Index; SHFM = Seattle Heart Failure Model.  
DATA PREPARATION AND MISSING DATA.  
Instead of performing multiple imputations of missing data, we favored a more conservative 
approach and included in the analysis only patients in whom the variables needed to estimate each 
of the aforementioned scores were available. In accordance with the design of the study, all 
variables needed to estimate the CHARM, the GISSI-HF, and the MAGGIC scores were collected 
in the registry. The only uncollected variables for calculating the SHFM score were percentage 
lymphocytes and ventricular assist device implantation, to which we respectively assigned set 
values of 20% (normal) and “no,” considering the probable low prevalence of ventricular assist 
devices in this population.  
 
After a first selection of patients, a significant number of data were missing only for the 
following variables: “uric acid,” used to estimate both the SHFM and the GISSI-HF score, and 
“total cholesterol,” used to estimate the SHFM score (Table 1). Instead of imputing these missing 
data, we created a simplified version of both the SHFM and the GISSI-HF score, which did not 
comprise these 2 variables, and to be used only for patients in which they were not available. 
When comparing the complete and simplified SHFM and GISSI-HF scores in patients who had 
both uric acid and total cholesterol were available, the correlation between the complete and 
simplified version was very high (SHFM: r = 0.88; p < 0.001; GISSI-HF: r = 0.98; p < 0.001). 
TABLE 1 Main Characteristics of the Study Population and by Status at 1-Year Follow-Up 
 
Total  
(N = 6,161; 100%) 
Alive  
(n = 5,653; 91.8%) 
Dead  
(n = 508; 8.2%) 
p Value C G M S 
         
Characteristics         
Survival probability         
CHARM  83.1 ± 8.4 83.6 ± 8.1 76.5 ± 8.6 <0.001 ●    
GISSI-HF  84.9 ± 12.9 86.1 ± 11.6 72.8 ± 18.9 <0.001  ●   
MAGGIC  89.4 ± 7.6 90.0 ± 6.9 82.2 ± 10.7 <0.001   ●  
SHFM  93.3 ± 9.1 93.8 ± 8.2 87.6 ± 14.1 <0.001    ● 
Age, yrs  64.9 ± 13.2 64.4 ± 13.1 69.8 ± 13.2 <0.001 ✔ ✔ ✔ ✔ 
Male 71.8 71.3 77.4 0.003 ✔ ✔ ✔ ✔ 
Weight, kg  79.9 ± 16.8 80.4 ± 16.7 74.6 ± 16.4 <0.001    ✔ 
BMI, kg/m2  28.1 ± 5.1 28.3 ± 5.1 26.5 ± 5.1 <0.001 ✔ ✔ ✔  
HF history         
Overall  91.3 91.4 90.4 0.405     
With previous hospitalization only  43.5 42.8 51.4 <0.001 ✔    
>12 months  59.8 60.9 47.3 <0.001 ✔  ✔  
Heart rate, beats/min  72.8 ± 15.5 72.5 ± 15.4 76.2 ± 17.0 <0.001 ✔    
Systolic BP, mm Hg  124.4 ± 20.6 125.0 ± 20.5 118.0 ± 21.0 <0.001  ✔ ✔ ✔ 
Diastolic BP, mm Hg  73.6 ± 11.9 74.0 ± 11.9 69.1 ± 12.4 <0.001 ✔    
Ischemic heart disease primary etiology  42.7 41.8 52.2 <0.001    ✔ 
Smoking status     0.906 ✔  ✔  
Current  11.4 11.4 10.8      
Former  42.0 41.9 42.5      
Never  46.6 46.6 46.7      
Atrial fibrillation  36.8 35.9 46.3 <0.001 ✔    
Diabetes mellitus  32.4 31.9 37.6 0.009 ✔ ✔ ✔  
Diabetes mellitus treated with insulin  11.9 11.5 16.6 <0.001 ✔    
Previous MI/angina  40.4 39.5 49.4 <0.001 ✔    
COPD  15.1 14.8 18.9 0.014  ✔ ✔  
Device therapy         ✔ 
CRT-D  10.5 10.1 14.6 0.002     
CRT-P  1.9 1.9 1.4 0.369     
ICD  16.7 17.1 13.2 0.025     
PM  5.6 5.4 7.5 0.047     
  
Clinical presentation         
NYHA functional class    <0.001 ✔ ✔ ✔ ✔ 
I  17.4 18.4 5.7      
II  57.6 58.9 44.1      
III  23.3 21.4 44.5      
IV  1.7 1.4 5.7      
Pulmonary rales  15.0 13.6 30.3 <0.001 ✔    
Peripheral edema  20.3 18.9 36.2 <0.001 ✔    
Mitral regurgitation  28.1 27.2 38.2 <0.001 ✔    
Aortic stenosis  4.3 3.8 9.3 <0.001  ✔   
         
Labs results         
Hemoglobin (g/dl)  13.3 ± 1.9 13.4 ± 1.8 12.3 ± 2.1 <0.001  ✔  ✔ 
Serum creatinine (mg/dl)  1.30 ± 2.62 1.28 ± 2.72 1.56 ± 1.04 <0.001   ✔  
eGFR (MDRD)  65.2 ± 26.3 66.3 ± 26.2 52.9 ± 23.9 <0.001  ✔   
Sodium (mEq/l)  139.4 ± 3.8 139.5 ± 3.6 138.0 ± 4.7 <0.001    ✔ 
Total cholesterol (mg/dl)  
167.3 ± 44.8  
(n = 4,792) 
168.1 ± 44.5  
(n = 4,433) 
158.3 ± 47.5  
(n = 359) 
<0.001    ✔ 
Uric acid (mg/dl)  
6.9 ± 2.7  
(n = 4,175) 
6.8 ± 2.5  
(n =3,838) 
7.6 ± 4.3  
(n = 337) 
<0.001  ✔  ✔ 
Outpatient visit: investigations/procedures         
BBB (LBBB or QRS duration>120)  43.8 42.9 53.5 <0.001 ✔   ✔ 
Cardiac enlargement, chest x-ray  29.2 28.7 33.7 0.020 ✔    
Pulmonary congestion, chest x-ray  13.4 12.8 19.3 <0.001 ✔    
LVEF  37.8 ± 13.7 38.1 ± 13.7 35.3 ± 13.8 <0.001 ✔ ✔ ✔ ✔ 
LVEF <40%  58.3 57.9 63.0 <0.001     
Medications         
ACE inhibitors  66.4 66.8 60.8 0.006   ✔ ✔ 
Angiotensin II receptor blockers  24.4 24.9 19.3 0.005   ✔ ✔ 
Beta-blockers  89.0 89.7 80.7 <0.001   ✔ ✔ 
Mineralocorticoid receptor antagonists  59.6 59.5 61.4 0.396    ✔ 
Statins  61.9 62.3 57.9 0.050    ✔ 
Diuretics oral  83.4 82.7 91.1 <0.001    ✔ 
Furosemide dose equivalence, median  
(1st, 3rd interquartile) 
40 (40,80) 40 (37.5,80) 80 (40,120) <0.001    ✔ 
Allopurinol  20.8 20.0 29.3 <0.001    ✔ 
         
 
Values are mean _ SD or %, unless otherwise noted. 
ACE = angiotensin-converting enzyme; BBB = bundle branch block; BMI = body mass index; BP = blood pressure; CHARM = Candesartan in Heart Failure-Assessment of Reduction in Mortality; COPD = 
chronic obstructive pulmonary disease; CRT-D/P = cardiac resynchronization therapy-defibrillator/pacemaker; eGFR = estimated glomerular filtration rate; GISSI-HF = Gruppo Italiano per lo Studio della 
Streptochinasi nell’Infarto Miocardico-Heart Failure; HF = heart failure; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MAGGIC = 
Meta-analysis Global Group in Chronic Heart Failure; MDRD = modification of diet in renal disease; MI = myocardial infarction; NYHA = New York Heart Association functional class; PM = pacemaker; 
SHFM = Seattle Heart Failure Model. 
 
STATISTICAL ANALYSIS.  
The characteristics of all patients at baseline and the characteristics of patients alive and dead at 1-year 
follow-up were summarized as means with SDs for continuous variables and as percentages for 
categorical variables, and compared with the use of Student t tests for continuous variables and chi-square 
tests for categorical variables. Observed versus model-predicted 1-year all-cause mortality was compared 
for quintiles of death probability estimated by each score, to evaluate the performance of each score at 
different levels of risk. Receiver operator characteristic (ROC) curves were generated to estimate the 
accuracy of each score in predicting 1-year all-cause mortality. The area under each ROC curve (AUC) 
was calculated and each AUC was compared with the best AUC using the Wald test to highlight 
significant differences and identify whether a more accurate prognostic score could be identified. A 2-
sided p value of <0.05 was considered statistically significant. All analyses were performed using SAS 
statistical software version 9.3 (SAS Institute, Inc., Cary, North Carolina).  
RESULTS  
A total of 9,428 chronic HF patients were enrolled in the registry. After applying our inclusion and 
exclusion criteria (Figure 1), 6,161 patients who completed the 1-year follow-up visit were entered in the 
final analysis. The clinical characteristics of patients included in the analysis, as compared to those 
excluded because of missing data, were substantially similar, including age (64.9 ± 13.2 years vs. 65.1 ± 
13.7 years; p = 0.244), male sex prevalence (71.8% vs. 71.1%; p = 0.474), systolic blood pressure (124 ± 
21 mm Hg vs. 124 ± 22 mm Hg; p = 0.789), serum creatinine (1.30 ± 0.80 mg/dl vs. 1.23 ± 0.68 mg/dl; p 
= 0. 690), and ischemic heart disease etiology (42.7% vs. 43.4%; p = 0.50).  
 
At 1-year follow-up, 508 patients (8.2%) had died. Table 1 shows the baseline characteristics of the 
overall population, and the comparison between those who were alive and those dead at 1-year follow up. 
Most covariates used in the risk score models were significantly different between the 2 groups (Table 1). 
In particular, at baseline, patients who had died at the time of scheduled follow-up, as compared to those 
who were alive, were significantly older, and had a more recent onset of HF with previous 
hospitalizations, a worse clinical presentation, and a lower LVEF. In addition, the use of HF-
recommended medications was significantly lower in those who had died at follow-up, with a 
significantly lower prevalence of an implanted implantable cardioverterdefibrillator (ICD) (Table 1).  
 
The CHARM, GISSI-HF, MAGGIC, and SHFM risk scores were retrospectively calculated for each 
patient and the distribution of each risk score in the study population is shown in Online Figure 1. 
Regardless of the risk score used, the average probability of survival was significantly higher in those 
who were alive at follow-up (Table 1). The observed- to- predicted survival ratios were the following: 
CHARM: 1.10, GISSI-HF: 1.08, MAGGIC: 1.03, and SHFM: 0.98, suggesting some over prediction of 
mortality by all scores except the SHFM.  
 
The performance of each score is shown in Figure 2. Discrimination at the individual patient level was 
good overall (AUC >0.700), with the MAGGIC (AUC = 0.743) and the SHFM (AUC = 0.714), 
respectively, appearing to have the best and the worst accuracy, with a significant statistical difference 
(Figure 2).  
  
FIGURE 2. Receiver Operating Characteristic Curves Comparing the Areas 





AUC = area under the curve; other abbreviations as in Figure 1. 
Histograms in Figure 3 show the observed versus model-predicted 1-year mortality for patients 
classified into quintiles of death probability estimated by each score. There was an over prediction of 
mortality for most risk groups using either the CHARM or the GISSI-HF score, whereas the SHFM score 
under predicted mortality in all risk groups except the highest. Despite some modest overestimation in the 
mid-probability range, the MAGGIC score showed the best overall accuracy in predicting 1-year 
mortality. Nonetheless, the Hosmer-Lemeshow goodness- of-fit test was <0.001 for all scores, which 
confirms the lack of fits of the models. 
  





Abbreviations as in Figure 1. 
Less than 4% of the case report forms (n = 241 of 6,161; 3.91%) had a response to the question “Was 
prognosis evaluated using a risk score?”, and in front of a list of 7 prognostic risk scores, the majority had 
a negative answer. Indeed, probability of risk was estimated in only 16 patients overall using the SHFM.  
DISCUSSION  
This is one of the few analyses in the literature that has compared the performance of multiple existing 
prognostic risk scores in a real-world population of ambulatory HF patients enrolled in a multinational 
and contemporary registry. We showed a significant difference in the accuracy of 4 different risk scores 
predicting all-cause mortality, with the MAGGIC risk score outperforming others, particularly the more 
popular SHFM. Nonetheless, calibration at different levels of risk was still imperfect for most scores, 
with a general trend toward overestimation of risk, which could in part justify why <1% of patients 
received a prognostic estimate from their enrolling physician.  
  
Table 2 summarizes the main characteristics of prognostic risk scores tested in this analysis. In 
particular, despite its subsequent validation and wide use, the SHFM score was originally derived from a 
sample of only approximately 1,000 chronic HF patients with reduced LVEF enrolled more than 20 years 
ago (2). Since then, the management and treatment of HF has changed substantially. Thus, the SHFM 
discrimination capacity in external validation cohorts has been recently estimated between 0.63 and 0.81 
(6), with an AUC as low as 0.66 in a more contemporary sample of more than 10,000 chronic HF patients 
enrolled between 2005 and 2008 (5). It is no surprise, therefore, to find that it performed more poorly than 
other scores in our analysis (AUC = 0.714). However, we unexpectedly found that it generally determined 
a modest underestimation and not overestimation of the risk of death, as did the other scores. The 
explanation for this finding is unclear, but it most likely relates to the excessive protective weight 
assigned to ICDs in the SHFM. Despite being the oldest risk score among those used in this analysis 
(Table 2), the SHFM is the only 1 that accounts for the presence of cardiac implantable electronic devices 
in risk estimation (Table 1), attributing a substantial reduction in the risk of death when the implantation 
of an ICD (with or without biventricular pacemaker capability) has already been performed or has been 
planned (2). At a closer look, device information (as well as beta-blocker medications) were not available 
in the original SHFM derivation database, and hazard ratios for these variables in the SHFM score were 
estimated from published literature “with the use of effects seen in large published trials” (2). These 
effects were obtained before the widespread implementation of triple neuro humoral blockade in HF, and 
have been nowadays largely downsized in patients receiving optimal HF medical treatment (18). Thus, 
when applied to a well-treated population such as ours, in which more than one-fourth of the patients had 
an ICD in place at the time of enrollment, and approximately one-half of the remaining had an ICD 
implantation planned in the near term (data not shown), they may have determined a reduction in the 
estimation of risk in a considerable proportion of patients. 
  
TABLE 2 Main Characteristics of Prognostic Risk Scores for Chronic HF Patients* 
 CHARM GISSI-HF MAGGIC SHFM 
     
Characteristics of score 
development population 
    
Sample size  
7,599 from 3 
RCT 
6,975 from 1 RCT 
39,372 from 30 
studies (6 RCT) 
1,125 from 1 RCT 
Mean age, yrs  66 68 68 65 
Women  31 ~22 35 34 
Ischemic etiology  ~70 40 54 63 





Both, ~75% reduced Reduced only 
Acute/chronic  HF Chronic Chronic Both Chronic 
HF treatments     
ACEi or ARB  41 93 67 99 
Beta-blockers  55 62 34 0 
MRA  17 40 21 3 
Diuretics  83 90 82 100 
ICD  0 7 NA 0 
Follow-up information     
Median time  38 months 48 months 30 months 14 months 
Total mortality  24.1 28.2 40.2 35.8 
Main risk score outcome  
All-cause 
mortality at 2 yrs 
All-cause mortality 
at 2 and 4 yrs 
All-cause mortality 
at 1 and 3 yrs 
All-cause mortality at 1, 2, 
and 5 yrs 
Time period     
Years of data collection  1999 to 2001 2002 to 2005 1992 to 2009 1992 to 1994 
Year of publication  2006 2013 2012 2006 
Methodology     
Initial validation in 
independent cohort 
No, only internal No, only internal No, only internal 
Yes, 9,942 patients from 5 
cohorts (1997 to 2001) 
Subsequent validation in 
independent cohort 
No No Yes, 2 cohorts (5,9) Yes, widely (6) 
Number of variables included  NA 25 31 31 
Number of variables in final 
model  
24 12 13 24 
Imputation of missing 
variables  
No Yes Yes 
Only in the validation 
cohorts 
     
 
Values are %, unless otherwise noted. *The characteristics of the whole population were derived from the original publication of the 
CHARM (27), the MAGGIC (28), the GISSI-HF (7) and the SHFM (29) studies. ACEi = angiotensin-converting enzyme inhibitor; 
ARB = angiotensin II receptor blocker; MRA = mineralocorticoid receptor antagonists; NA = not available; RCT = randomized 
controlled trial; other abbreviations as in Table 1. 
On the other hand, we found that the MAGGIC score had the best overall accuracy in predicting 1-
year survival (AUC = 0.743), with some modest overestimation of risk only in the mid-probability range 
(Figures 2 and 3). This finding is in line with what has been observed in a similar analysis testing the 
performance of the MAGGIC score in a large administrative Swedish registry of more than 51,000 HF 
patients, which reported an AUC as high as 0.781 and a slight overestimation and underestimation of risk 
of 1-year mortality in the lowest and highest risk groups, respectively (9). Recent clinical trials of device 
(18) and drug therapies (19) have shown a progressive improvement with time in the prognosis of chronic 
HF with reduced LVEF treated with optimal medical therapy, with an overall mortality as low as 5% per 
year. In this contemporary multinational European registry, we observed a relevant improvement in the 
use of HF treatments (11), with percentages of patients treated with renin-angiotensin system blockers 
and beta-blockers as high as 90%, and a similar 1-year mortality of 8.2%. This mortality rate remains 
slightly higher than the 5% mortality observed in contemporary clinical trials, but it is significantly lower 
than that recorded in older derivation cohorts of prognostic risk score, particularly the SHFM (Table 2). 
Thus, the general over prediction of risk shown by the CHARM, the MAGGIC, and the GISSI-HF scores 
is most likely due to the significant improvement in the treatment of HF patients since the conception of 
these risk scores (Table 2).  
  
It has been argued that prognostic risk scores, by incorporating multiple clinical variables, may be of 
greater help in estimating the risk of death from competing causes rather than sudden cardiac death (20). 
For example, it has been shown that with the increase in SHFM score, the rise in the risk of HF death is 
greater than that in the risk of sudden cardiac death (21). Unfortunately, a centralized validation of causes 
of death was not performed, but local investigators reported that approximately one-half of deaths in our 
registry were due to cardiovascular reasons (10). Thus, we foresee that the role of prognostic risk scores 
will become increasingly relevant in the near future, considering that the annual rate of sudden death has 
been significantly falling over the past 20 years (22), whereas non cardiac mortality has become the most 
relevant issue, particularly in patients with HF with preserved LVEF (23). Future prognostic risk models 
should be designed to also include this specific group of HF patients, which were a minority in previous 
derivation cohorts (Table 2) and accounted for approximately 40% of our study population (Table 1).  
 
A final finding, although apparently minor, is the confirmation that such risk scores are not routinely 
used in daily clinical practice (1). Web-based applications have been developed for the SHFM and 
MAGGIC risk score to facilitate their use, and the MAGGIC software also allows for 2 of the 13 
variables to be unknown. The GISSI-HF investigators proposed a practical nomogram usable at the desk 
to estimate the risk of death in individual patients (7). Despite these efforts, <1% of patients enrolled in 
this contemporary European registry received a prognostic estimate. Unfortunately, risk scores are known 
to perform very poorly for short-term medical decisions about individual patients (1), and this is probably 
discouraging their current application. A recent analysis of 10,930 ambulatory HF patients confirmed this 
open issue, showing that only 8 of 1,661 patients who died in the year after study enrollment had a >50% 
mortality rate predicted using the SHFM (sensitivity, 0.5%), and only 52 using the MAGGIC score 
(sensitivity, 3.1%), with the majority of deaths occurring in those with an estimated probability of 
survival >80% (5). Critical medical decisions (in cardiology as in other disciplines of medicines) are 
based on life expectancy, and prognostication remains essential to developing appropriate treatment plans 
and to relaying truthful information to the patient and his/her family members. Thus, further research is 
needed in search of increased accuracy and precision at the individual, more than at the population level.   
 
One major limitation of risk score models in HF is the absence of impact analyses (24). Studies to 
evaluate the effect of using a prognostic model on current medical practice and on patient outcome would 
be informative and could lead to clinical implementation of such a model. An impact analysis could 
determine whether the use of the model is better than the usual care, and this remains an unmet need. In 
addition, the present prognostic scores, mostly generated by selected populations included in randomized 
controlled trials, might be used to assess the severity of HF in trial populations, either to characterize and 
compare previous trials targets or to assess the HF severity in populations enrolled in current prospective 
trials. However, as far as we know, this potentially interesting application of available scores has never 
been considered.  
STUDY LIMITATIONS.  
This work has several strengths and limitations to be acknowledged. Our analysis included 
ambulatory HF patients only, and tested prognostic scores which were specifically designed for this 
population. On the contrary, a previous analysis similar to ours also included HF patients discharged from 
hospital (9), for whom different and specific prognostic models should be applied (25). In addition, there 
was a relatively small amount of missing data on the candidate variables considering the multinational 
and voluntary nature of the registry. Thus, we refrained from using multiple imputation of missing data, 
and at the same time we made sure that the characteristics of included versus excluded patients were 
similar. Finally, we used real-world data collected in recent years (2011–2013), providing the most recent 
validation of the 4 risk scores used to date. This approach appears more consistent than the extrapolation 
of data from administrative electronic health records, which frequently do not record clinical variables 
that are very relevant in the prediction of outcomes, such as New York Heart Association (NYHA) 
functional class (5).  
  
Among the limitations, we unfortunately could not test additional prognostic scores due to the lack of 
candidate variables in our registry, particularly those obtained from cardiopulmonary exercise tests. We 
created a simplified version of the SHFM and GISSI-HF for patients who were missing uric acid and total 
cholesterol values, but reported an excellent correlation between the complete and simplified versions in 
those who had both these variables available (see Methods section).  
 
Our registry namely recorded a 1-year follow-up time point only. This might have determined an 
underestimation of the number of events against the GISSI-HF and CHARM scores, which were 
originally designed to predict 2-year all-cause mortality (Table 2). Nonetheless, as explained in the 
Methods section, approximately 10% of our patients had a follow-up of 2-years or longer, which might 
have partially mitigated this limitation. Our present analysis accounted neither for hospitalizations nor for 
specific causes of death, which were missing in about one-third of our ambulatory HF population (10). 
Thus, we elected to examine only prognostic risk scores specifically designed for total mortality.  
 
The average age of the studied population was relatively young (<70 years of age): separate analysis 
in an older population would be clinically relevant because this subgroup of patients presents more 
challenging issues in prognostication and in the choice of the most appropriate therapy. In addition, only 
approximately one-third of patients in this registry were female, as was the case in the datasets from 
which these scores were developed (Table 2). This seems to be a general limitation inherent to the 
cardiology setting that does not include the universe of HF patients (26). The application and reliability of 
these score in female HF patients remains an open issue that may warrant further research. Finally, we 
can only speculate that the wider racial/ethnic composition of the MAGGIC derivation sample may have 
contributed to its greater accuracy in our multinational European cohort.  
CONCLUSIONS  
Prognostication in chronic HF patients has become increasingly important. We used a large 
contemporary and multinational ambulatory HF population to confirm that the performance of available 
prognostic risk scores is still limited. In our analysis, the most recent MAGGIC risk model appeared to be 
more accurate than the older CHARM and SHFM models in predicting 1-year mortality at the population 
level. However, investigators in this European registry were reluctant to use these scores, likely because 
their reliability at the individual patient level is known to be very poor. With the progressive improvement 
in HF therapeutic management and resulting decrease in mortality new, more precise, and thereby more 
clinically useful, prognostic tools are needed.  
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